Sarah Buchik

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised H1, a global healthcare data technology company, on its acquisition of Ribbon Health.

Cooley advised Brigit, a financial health technology company, on its definitive agreement to be acquired by Upbound Group (Nasdaq: UPBD), a technology- and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, for total consideration of up to $460 million.

Cooley advised Battery Ventures, a global, technology-focused investment firm, on its strategic, majority growth investment in QSR Automations, a global leader in restaurant technology.

Cooley advised Avid Bioservices (Nasdaq: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, on its definitive merger agreement to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.